1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic denervation potentiates GABAergic inhibition in the mouse neostriatum in vitro

Neuroscience

Volumn 71, Issue 3, 1996, Pages 691-700

  Schlosser B ^a   Muller A ^a   Sutor, B ^a   Ten Bruggencate, G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

AMPA receptor; GABA; Glutamate; MPTP; NMDA receptor; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; AMPA RECEPTOR; BICUCULLINE; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; MAGNESIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; ELECTROPHYSIOLOGY; MALE; MOUSE; NEOSTRIATUM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

EID: 0343833112     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(95)00474-2     Document Type: Article

References (49)

1. Akaike A., Ohno Y., Sasa M. and Takaori S. (1987) Excitatory and inhibitory effects of dopamine on neuronal activity of the caudate nucleus neurons in vitro. Brain Res. 418, 262-272.
2. Albin R. L., Young A. B. and Penney J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375.
3. Arai N., Misugi K., Goshima Y. and Misu Y. (1990) Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for Parkinsonism. Brain Res. 515, 57-63.
4. Aziz T. Z., Peggs D., Sambrook M. A. and Crossman A. R. (1991) Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism in the primate. Movement Disorders 6, 288-292.
5. Burns R. A., Chieuh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M. and Kolpin J. J. (1983) A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-phenyl-1,2,3,6-tetrahydropyridine. Proc. natn. Acad. Sci. U.S.A. 80, 4546-4550.
6. Calabresi P., Mercuri N. B. and Bernardi G. (1990) Synaptic and intrinsic control of membrane excitability of neostriatal neurons: II. An in vitro analysis. J. Neurophysiol. 63, 663-675.
7. Calabresi P., Mercuri N. B., Sancesario G. and Bernardi G. (1993) Electrophysiology of dopamine-denervated striatal neurons. Brain 116, 433-452.
8. Calabresi P., Mercuri N., Stanzione P., Stefani A. and Bernardi G. (1987) Intracellular studies on the dopamine-induced firing inhibition of neostriatal neurons in vitro: evidence for D1 receptor involvement. Neuroscience 20, 757-771.
9. Cepeda C., Buchwald N. A. and Levine M. S. (1993) Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc. natn. Acad. Sci. U.S.A. 90, 9576-9580.
10. Cherubini E., Herrling P. L., Lanfumey L. and Stanzione P. (1988) Excitatory amino acids in synaptic excitation of rat striatal neurons in vitro. J. Physiol. 400, 677-690.
11. +); evidence for free radical involvement. J. Neurochem 58, 786-789.
12. Cordingley G. E. and Weight F. F. (1986) Non-cholinergic synaptic excitation in neostriatum: pharmacological evidence for mediation by a glutamate-like transmitter. Br. J. Pharmac. 88, 847-856.
13. Date I., Felten D. and Felten S. Y. (1990) Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 519, 266-276.
14. Fonnum F., Storm-Mathisen J. and Divac I. (1981) Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience 6, 863-873.
15. Gupta M., Gupta B. K., Thomas R., Bruemmer V., Sladek J. R. Jr. and Felten D. L. (1986) Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults. Neurosci. Lett. 70, 326-331.
16. Hu X. T. and Wang R. Y. (1988) Comparison of effects of D-1 and D-2 dopamine receptor agonists on neurons in the rat caudate putamen: An electrophysiological study. J. Neurosci. 8, 4340-4348.
17. Jackson D., Abercrombie E. D. and Zigmond M. J. (1993) Impact of L-DOPA on striatal acetylcholine release: Effects of 6-hydroxydopamine. J. Pharmac. exp. Ther. 267, 912-918.
18. Javoy-Agid F. and Agid Y. (1980) Is the mesocortical dopaminergic system involved in Parkinson's disease? Neurology 30, 1326-1333.
19. Jiang Z. G. and North R. A. (1991) Membrane properties and synaptic responses of rat striatal neurons in vitro. J. Physiol. 443, 533-553.
20. Kish S., Rajput A., Gilbert J., Rozdilsky B., Chang L. J., Shannak K. and Hornykiewicz O. (1986) GABA-Dopamine relationship in Parkinson's disease striatum. Adv. Neurol. 45, 75-77.
21. Kupsch A., Gerlach M., Pupeter S. C., Sautter J., Dir A., Arnold G., Opitz W., Przuntek H., Riederer P. and Oertel W. (1995) Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. NeuroReport, (in press).
22. Langston J. W., Forno L. S., Rebert C. S. and Irwin J. (1984) Selective nigral toxicity after systemic administration of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292, 390-394.
23. Lindefors N., Brodin E., Tossmann U., Segovia J. and Ungerstedt U. (1989) Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation. Expl Brain Res. 74, 527-534.
24. McCrodden J. M., Tipton K. F. and Sullivan J. P. (1990) The neurotoxicity of MPTP and its relevance to Parkinson's disease. Pharmac. Toxic. 67, 8-13.
25. Mercuri N., Bernardi G., Calabresi P., Cotugno A., Levi G. and Stanzione P. (1985) Dopamine decreases cell excitability in rat striatal neurons by pre-and postsynaptic mechanisms. Brain Res. 358, 110-121.
26. Misgeld U., Okada Y. and Hassler R. (1979) Locally evoked potentials in slices of rat neostriatum: A tool for the investigation of intrinsic excitatory processes. Expl Brain Res. 34, 575-590.
27. Misgeld U., Wagner A. and Ohno T. (1982) Depolarizing IPSPs and depolarization by GABA in rat neostriatum cell in vitro. Expl Brain Res. 45, 108-114.
28. Müller A., Schlösser B., Sutor B. and ten Bruggencate G. (1994) Chronic dopaminergic denervation induces potentiation of GABAergic inhibition in the mouse neostriatum. Pflügers Arch. 426, Suppl. l, R96.
29. Nishi K., Kondo T. and Narabayashi H. (1989) Difference in recovery patterns of striatal dopamine content, tyrosine hydroxylase activity and total biopterin after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration: a comparison of young and older mice. Brain Res. 489, 157-162.
30. Park M. R., Lighthall J. W. and Kitai S. T. (1980) Recurrent inhibition in the rat neostriatum. Brain Res. 194, 359-369.
31. Perry E. K., Parry R. H. and Tomlinson B. E. (1982) The influence of agonal status on some neurochemical activities of post-mortem human brain tissue. Neurosci. Lett. 29, 303-308.
32. Rutherford A., Garcia-Munoz M. and Arbuthnott G. W. (1988) An afterhyperpolarization recorded in striatal cell 'in vitro': effect of dopamine administration. Expl Brain Res. 71, 399-405.
33. Samuel D., Kumar U. and Nieollon A. (1988) Gamma-aminobutyric acid function in the rat striatum is under the double influence of nigrostriatal dopaminergic and thalamostriatal inputs: Two modes of regulation. J. Neurochem. 511, 1704-1710.
34. o on glutamatergic synaptic transmission in control and MPTP-pretreated mice. Pflügers Arch. 422, Suppl. 6, R48.
35. Schulz W. (1981) Depletion of dopamine in the striatum as an experimental model of Parkinsonism: direct effects and adaptive mechanisms. Prog. Neurobiol. 18, 121-166.
36. Segovia J., Armstrong D. M., Benzing W. C. and Hornby P. J. (1991) Striatal glutamic acid decarboxylase immunoreactivity is increased after dopaminergic deafferentiation: densitometric analysis. Neurosci. Let. 122, 252-256.
37. Segovia J., Tillakarante N. J. K., Whelan D., Tobin A. J. and Gale K. (1990) Parallel increases in striatal glutamic acid decarboxylase activity and mRNA levels in rats with lesions of the nigrostriatal pathway. Brain Res. 529, 345-348.
38. Soghomonian J. J. and Chesselet M. F. (1991) Lesions of the dopaminergic nigrostriatal pathway alter preprosomatostatin messenger RNA levels in the striatum, the entopeduncular nucleus and the lateral hypothalamus of the rat. Neuroscience 42, 49-59.
39. Soghomonian J. J., Gonzales C. and Chesselet M. F. (1992) Messenger RNAs encoding glutamate-decarboxylase are differentially affected by nigrostriatal lesions in subpopulations of striatal neurons. Brain Res. 576, 68-79.
40. Sonsalla P. and Heikkila R. E. (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmac. 129, 339-345.
41. Sundström E., Strömberg I., Tsutsumi T., Olson L. and Jonsson G. (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57 BE/6 mice. Comparison with three other strains of mice. Brain Res. 405, 26-38.
42. Tanaka Y., Nijima K., Mizuno Y. and Yoshida M. (1986) Changes in gamma-aminobutyrate, glutamate, aspartate, glycine and taurine contents in the striatum after unilateral nigrostnatal lesions in rats. Expl Neurol. 91, 259-268.
43. Tossmann U., Segovia J. and Ungerstedt U. (1986) Extracellular levels of amino acids in striatum and globus pallidus of 6-hydroxydopamine-lesioned rat measured by microdialysis. Acta physiol. scand. 127, 547-551.
44. Trulson M. E. and Arasteh K. (1986) Effects of dopamine and amphetamine on mouse caudate neurons recorded in vitro. Eur. J. Pharmac. 124, 161-165.
45. Voorn P., Roest G. and Groenewegen H. J. (1987) Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412, 391-396.
46. Wilson J. A., Wilson J. S. and Weight F. F. (1986) MPTP causes a non-reversible depression of synaptic transmission in mouse neostriatal brain slice. Brain Res. 368, 357-360.
47. Wüllner U., Brouillet E., Isacson O., Young A. B. and Penny J. B. (1993) Glutamate receptor binding sites in MPTP-treated mice. Expl Neurol. 121, 284-287.
48. Yamamoto C. (1973) Neurotransmitter actions studied in brain slices. Adv. Neurol. Sci. 17, 64-70.
49. Yoshida M. (1991) The neuronal mechanism underlying Parkinsonism and dyskinesia: differential roles of the putamen and caudate nucleus. Neurosci. Res. 12, 31-40.